tetano
Editor, Senior Moderator
J Med Virol
. 2023 Aug;95(8):e29010.
doi: 10.1002/jmv.29010. Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study
Gerard Moreno[SUP] 1 [/SUP], Raquel Carbonell[SUP] 1 [/SUP], Emili Díaz[SUP] 2 [/SUP], Ignacio Martín-Loeches[SUP] 3 [/SUP], Marcos I Restrepo[SUP] 4 [/SUP], Luis F Reyes[SUP] 5 [/SUP], Jordi Solé-Violán[SUP] 6 [/SUP], María Bodí[SUP] 1 7 [/SUP], Laura Canadell[SUP] 8 [/SUP], Juan Guardiola[SUP] 9 [/SUP], Sandra Trefler[SUP] 1 [/SUP], Loreto Vidaur[SUP] 10 [/SUP], Elisabeth Papiol[SUP] 11 [/SUP], Lorenzo Socias[SUP] 12 [/SUP], Eudald Correig[SUP] 13 [/SUP], Judith Marín-Corral[SUP] 14 [/SUP], Alejandro Rodríguez[SUP] 1 7 [/SUP]; GETGAG Working Group
Affiliations
The aim of this study is to investigate the effectiveness of prolonged versus standard course oseltamivir treatment among critically ill patients with severe influenza. A retrospective study of a prospectively collected database including adults with influenza infection admitted to 184 intensive care units (ICUs) in Spain from 2009 to 2018. Prolonged oseltamivir was defined if patients received the treatment beyond 5 days, whereas the standard-course group received oseltamivir for 5 days. The primary outcome was all-cause ICU mortality. Propensity score matching (PSM) was constructed, and the outcome was investigated through Cox regression and RCSs. Two thousand three hundred and ninety-seven subjects were included, of whom 1943 (81.1%) received prolonged oseltamivir and 454 (18.9%) received standard treatment. An optimal full matching algorithm was performed by matching 2171 patients, 1750 treated in the prolonged oseltamivir group and 421 controls in the standard oseltamivir group. After PSM, 387 (22.1%) patients in the prolonged oseltamivir and 119 (28.3%) patients in the standard group died (p = 0.009). After adjusting confounding factors, prolonged oseltamivir significantly reduced ICU mortality (odds ratio [OR]: 0.53, 95% confidence interval [CI]: 0.40-0.69). Prolonged oseltamivir may have protective effects on survival at Day 10 compared with a standard treatment course. Sensitivity analysis confirmed these findings. Compared with standard treatment, prolonged oseltamivir was associated with reduced ICU mortality in critically ill patients with severe influenza. Clinicians should consider extending the oseltamivir treatment duration to 10 days, particularly in higher-risk groups of prolonged viral shedding. Further randomized controlled trials are warranted to confirm these findings.
Keywords: ICU mortality; critically ill; prolonged oseltamivir; severe influenza.
. 2023 Aug;95(8):e29010.
doi: 10.1002/jmv.29010. Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study
Gerard Moreno[SUP] 1 [/SUP], Raquel Carbonell[SUP] 1 [/SUP], Emili Díaz[SUP] 2 [/SUP], Ignacio Martín-Loeches[SUP] 3 [/SUP], Marcos I Restrepo[SUP] 4 [/SUP], Luis F Reyes[SUP] 5 [/SUP], Jordi Solé-Violán[SUP] 6 [/SUP], María Bodí[SUP] 1 7 [/SUP], Laura Canadell[SUP] 8 [/SUP], Juan Guardiola[SUP] 9 [/SUP], Sandra Trefler[SUP] 1 [/SUP], Loreto Vidaur[SUP] 10 [/SUP], Elisabeth Papiol[SUP] 11 [/SUP], Lorenzo Socias[SUP] 12 [/SUP], Eudald Correig[SUP] 13 [/SUP], Judith Marín-Corral[SUP] 14 [/SUP], Alejandro Rodríguez[SUP] 1 7 [/SUP]; GETGAG Working Group
Affiliations
- PMID: 37537755
- DOI: 10.1002/jmv.29010
The aim of this study is to investigate the effectiveness of prolonged versus standard course oseltamivir treatment among critically ill patients with severe influenza. A retrospective study of a prospectively collected database including adults with influenza infection admitted to 184 intensive care units (ICUs) in Spain from 2009 to 2018. Prolonged oseltamivir was defined if patients received the treatment beyond 5 days, whereas the standard-course group received oseltamivir for 5 days. The primary outcome was all-cause ICU mortality. Propensity score matching (PSM) was constructed, and the outcome was investigated through Cox regression and RCSs. Two thousand three hundred and ninety-seven subjects were included, of whom 1943 (81.1%) received prolonged oseltamivir and 454 (18.9%) received standard treatment. An optimal full matching algorithm was performed by matching 2171 patients, 1750 treated in the prolonged oseltamivir group and 421 controls in the standard oseltamivir group. After PSM, 387 (22.1%) patients in the prolonged oseltamivir and 119 (28.3%) patients in the standard group died (p = 0.009). After adjusting confounding factors, prolonged oseltamivir significantly reduced ICU mortality (odds ratio [OR]: 0.53, 95% confidence interval [CI]: 0.40-0.69). Prolonged oseltamivir may have protective effects on survival at Day 10 compared with a standard treatment course. Sensitivity analysis confirmed these findings. Compared with standard treatment, prolonged oseltamivir was associated with reduced ICU mortality in critically ill patients with severe influenza. Clinicians should consider extending the oseltamivir treatment duration to 10 days, particularly in higher-risk groups of prolonged viral shedding. Further randomized controlled trials are warranted to confirm these findings.
Keywords: ICU mortality; critically ill; prolonged oseltamivir; severe influenza.